Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bioavailability Study Design: Healthy Subjects Versus Patients01:15

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
Bioavailability Study Design: Single Versus Multiple Dose Studies01:11

Bioavailability Study Design: Single Versus Multiple Dose Studies

Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Inflammatory and Epigenetic Biomarkers in Prostate Disease: Current Evidence, Clinical Limitations, and Future Multimarker Strategies.

Diagnostics (Basel, Switzerland)·2026
Same author

Understanding Patient Preferences and Their Impact on Adherence to Glaucoma Therapy: A Multicenter Cross-Sectional Study.

Ophthalmology and therapy·2026
Same author

Genetic variants through exome sequencing in Spanish patients affected by primary congenital glaucoma and juvenile open-angle glaucoma.

Molecular vision·2026
Same author

Hypertensive phase after a novel small-lumen non-valved drainage device: predictive factors and two-year outcomes.

Japanese journal of ophthalmology·2025
Same author

Predictive factors for the success of the Paul glaucoma implant: a one-year multicenter prospective study.

Scientific reports·2025
Same author

Glaucoma diagnosis and treatment in the era of precision medicine.

Pharmacogenomics·2025
Same journal

Identifying patients with poor visual outcomes after primary rhegmatogenous retinal detachment surgery using machine learning.

The British journal of ophthalmology·2026
Same journal

Incidence of bilateral disease and choroidal neovascularisation in punctate inner choroiditis.

The British journal of ophthalmology·2026
Same journal

Reference map of multimodal vision deficits in intermediate age-related macular degeneration: contrast sensitivity and low-contrast visual acuity.

The British journal of ophthalmology·2026
Same journal

Commentary on 'identifying patients with poor visual outcomes after primary rhegmatogenous retinal detachment surgery using machine learning'.

The British journal of ophthalmology·2026
Same journal

Automated deep learning-based retinoschisis and detachment volume measurement in pathological myopia with posterior scleral contraction.

The British journal of ophthalmology·2026
Same journal

Bacterial keratitis: a global review of current practices, challenges and innovations.

The British journal of ophthalmology·2026
See all related articles

Related Experiment Videos

Spanish multicenter tafluprost tolerability study.

Elena Milla1, Oana Stirbu, Amanda Rey

  • 1Glaucoma and Genetics Unit, Institut Comtal d'Oftalmologia, Via Augusta 48-54, 2n 08006 BCN Barcelona, Spain. emillaright@gmail.com

The British Journal of Ophthalmology
|March 9, 2012
PubMed
Summary
This summary is machine-generated.

Preservative-free tafluprost eye drops effectively improved ocular surface symptoms and signs in glaucoma and ocular hypertension patients. This well-tolerated hypotensive agent is suitable for patients with pre-existing ocular surface issues.

Related Experiment Videos

Area of Science:

  • Ophthalmology
  • Ocular Surface Disease
  • Glaucoma Management

Background:

  • Glaucoma and ocular hypertension (OHT) management often involves topical medications.
  • Prostaglandin analogues are common first-line treatments, but preservatives can cause ocular surface toxicity.
  • Preservative-free formulations aim to improve tolerability and reduce ocular surface side effects.

Purpose of the Study:

  • To assess the ocular surface symptoms and signs in patients using preservative-free 0.0015% tafluprost.
  • To evaluate the efficacy and tolerability of preservative-free tafluprost in glaucoma and OHT patients.
  • To compare outcomes in treatment-naive patients versus those previously treated with other prostaglandin analogues.

Main Methods:

  • A prospective, non-interventional, multicentre, observational study.
  • 134 patients with glaucoma or OHT were enrolled.
  • Ocular surface symptoms and signs were evaluated at baseline, 1 month, and 3 months.

Main Results:

  • Significant improvement in all ocular surface symptoms was observed in both OHT and glaucoma patients by 3 months.
  • Ocular surface signs, including keratitis and conjunctival hyperaemia, improved in glaucoma patients; OHT patients showed improvement in most signs.
  • Preservative-free tafluprost demonstrated effective intraocular pressure (IOP) lowering in naive eyes (22.2% in OHT, 29.5% in glaucoma).

Conclusions:

  • Preservative-free 0.0015% tafluprost is well-tolerated and effective.
  • It is a suitable treatment option for patients with glaucoma or OHT, including those with ocular surface problems.
  • The formulation offers a favorable safety profile for long-term ocular surface health.